Greylin Investment Management Inc Has $223,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Greylin Investment Management Inc lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 15.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,115 shares of the biopharmaceutical company’s stock after selling 750 shares during the period. Greylin Investment Management Inc’s holdings in Bristol-Myers Squibb were worth $223,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of BMY. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb during the third quarter worth about $27,000. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $27,000. Accordant Advisory Group Inc bought a new stake in Bristol-Myers Squibb during the first quarter worth about $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded down $0.79 during trading hours on Thursday, reaching $41.55. The company’s stock had a trading volume of 12,432,686 shares, compared to its average volume of 15,505,270. The firm’s 50 day simple moving average is $48.02 and its 200-day simple moving average is $49.74. The company has a market capitalization of $84.23 billion, a price-to-earnings ratio of -13.40, a PEG ratio of 14.31 and a beta of 0.45. Bristol-Myers Squibb has a fifty-two week low of $41.46 and a fifty-two week high of $66.69. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.78%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. BMO Capital Markets lowered their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, Barclays lowered their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.